COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

被引：0
|
作者：
Gyldmark, M. [1 ]
Aultman, R. [1 ]
Siebert, U. [2 ]
Sabate, E. [3 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] UMIT Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[3] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73306-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A49 / A49
页数：1
相关论文
共 50 条
  • [21] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [22] Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    ANTICANCER RESEARCH, 2011, 31 (05) : 1777 - 1782
  • [23] Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
    Han, Jiaqi
    Xiao, Desheng
    Tan, Chongqing
    Zeng, Xiaohui
    Hu, Huabin
    Zeng, Shan
    Jiang, Qin
    She, Longjiang
    Yao, Linli
    Li, Li
    Tang, Lanhua
    Ma, Jian
    Huang, Jin
    Shen, Liangfang
    CANCER CONTROL, 2020, 27 (01)
  • [24] FOLFIRI plus bevacizumab versus FOLFIRI plus ramucirumab as second-line chemotherapy for metastatic colorectal cancer in the real-world
    Shimura, T.
    Kitagawa, M.
    Sugimura, N.
    Fukusada, S.
    Tanaka, M.
    Kataoka, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1439 - S1439
  • [25] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Xuetong Rong
    Haiyi Liu
    Hongmei Yu
    Jian Zhao
    Jie Wang
    Yusheng Wang
    Investigational New Drugs, 2022, 40 : 340 - 348
  • [26] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Rong, Xuetong
    Liu, Haiyi
    Yu, Hongmei
    Zhao, Jian
    Wang, Jie
    Wang, Yusheng
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 340 - 348
  • [27] Cost-effectiveness of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study
    Stintzing, Sebastian
    van Oostrum, Ilse
    Pescott, Chris P.
    Ronga, Philippe
    Heeg, Bart
    Heinemann, Volker
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 448 - 455
  • [28] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
  • [29] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 120 : 183 - 189
  • [30] A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI plus bevacizumab (FOLFIRI plus Bev)
    Rivers, Zachary
    Stenehjem, David D.
    Jacobson, Pamala
    Lou, Emil
    Nelson, Andrew
    Kuntz, Karen M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345